Kooperativer Bibliotheksverbund

UID:

Format: X, 311 p. 100 illus., 30 illus. in color. , online resource.

Edition: 1st ed. 2024.

ISBN: 9783031663567

Series Statement: Current Topics in Behavioral Neurosciences, 66

Content: This volume is unique in bringing the exciting range of antidepressant treatment developments together with a focus on their neurobiological mechanisms and how these interact with the known pathophysiology of depression. Current evidence for treatment efficacy is reviewed together with a discussion of where in the management pathway of this common condition, these new approaches might take their place.

Note: SSRIs A pharmacological cul-de-sac -- Neurobiology of SSRI withdrawal -- Pramipexole in the treatment of depression -- Opioid mechanisms in the treatment of depression -- Neuropsychological effects of antidepressants-translational studies -- KETAMINE FOR MAJOR DEPRESSIVE DISORDER -- Psilocybin and other classic psychedelics in depression -- Gut-brain axis and antidepressant treatment -- Anti-inflammatory drugs in the treatment of depression -- Mechanisms of TMS in Depression -- Mechanism of action of ECT in depression -- Vagal nerve stimulation in the treatment of depression.

In: Springer Nature eBook

Additional Edition: Printed edition: ISBN 9783031663550

Additional Edition: Printed edition: ISBN 9783031663574

Additional Edition: Printed edition: ISBN 9783031663581

Language: English

DOI: 10.1007/978-3-031-66356-7

URL: https://doi.org/10.1007/978-3-031-66356-7

URL: Volltext  (URL des Erstveröffentlichers)

URL: lizenzpflichtig

UID:

Format: 158 S.

Language: English

UID:

Format: 438 S. : , Ill.

Language: English

Subjects: Theology

UID:

Format: 1 Online-Ressource (x, 344 Seiten) : , Illustrationen.

ISBN: 978-3-642-35425-0

Series Statement: Current topics in behavioral neurosciences 14

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-642-35424-3

Language: English

Subjects: Psychology , Medicine

Keywords: Depression ; Neurobiologie ; Verhalten ; Aufsatzsammlung

DOI: 10.1007/978-3-642-35425-0

URL: Volltext

URL: http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025912393&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA

URL: http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025912393&sequence=000003&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA

UID:

Format: 21 S

Series Statement: Bulletin/University of the State of New York 1362

Language: Undetermined

UID:

Format: X, 344 Seiten , Ill., graph. Darst.

ISBN: 9783642354243 , 3642354246

Series Statement: Current topics in behavioral neurosciences 14

Language: English

UID:

Format: 20 S

Series Statement: Bulletin/University of the State of New York 1299

Language: Undetermined

UID:

Format: 36 S

Series Statement: Bulletin/University of the State of New York 1173

Language: Undetermined

UID:

Format: 84 S

Series Statement: Bulletin/University of the State of New York 1329

Language: Undetermined

UID:

Format: 1 online resource (314 pages)

Edition: 1st ed.

ISBN: 3-031-66356-X

Series Statement: Current Topics in Behavioral Neurosciences Series ; v.66

Note: Intro -- Preface -- Contents -- SSRIs in the Treatment of Depression: A Pharmacological CUL-DE-SAC? -- 1 Depression and Antidepressant Treatment -- 2 Development of SSRIs -- 3 Advantages of SSRIs -- 3.1 Simplicity of Dosing -- 3.2 Efficacy Against Anxiety Symptoms -- 3.3 Relative Safety in Overdose -- 4 Problems with SSRIs -- 4.1 Delayed Onset of Action -- 4.2 Limited Efficacy -- 4.3 Suicidality -- 4.4 Increased Anxiety Early in Treatment -- 4.5 Sleep Problems -- 4.6 Sexual Dysfunction -- 4.7 Emotional Blunting -- 4.8 Cognitive Impairment -- 4.9 Withdrawal Symptoms -- 5 Modifications of Selective Serotonin Reuptake Inhibition as a Therapeutic Mechanism -- 5.1 Dual Reuptake Inhibitors -- 5.2 Serotonin Reuptake Inhibition and Serotonin Receptor Activity -- 6 Other Potential Serotonin Receptor Sub-type Mechanisms -- 6.1 5-HT2A/2C Receptor Blockade -- 6.2 5-HT4 Receptor Agonism -- 6.3 5-HT7 Receptors -- 7 Conclusions -- References -- Mechanisms of SSRI Therapy and Discontinuation -- 1 SSRI Benefits and Adverse Effects -- 2 Mechanisms of SSRI Action -- 2.1 Importance of the 5-HT Transporter -- 2.2 Neuroadaptive Changes in 5-HT Neuron Function -- 2.3 Role of Adaptive Changes in Neural Plasticity -- 2.4 Rapid Acting Antidepressants -- Ketamine and Psychedelic Drugs -- 2.5 Depression Pathophysiology -- 2.6 A Neuropsychological Perspective of SSRI Action -- 3 SSRI Discontinuation -- 3.1 SSRI Discontinuation Syndrome -- 3.2 `Discontinuation´ vs. `Withdrawal´ -- 3.3 Discontinuation Risk Factors -- 3.4 Modelling SSRI Discontinuation in Animals -- 4 Mechanisms of SSRI Discontinuation -- 4.1 Role of 5-HT -- 4.2 Causal Link between 5-HT Changes and Behaviour -- 4.3 A Role for Other Neurotransmitter Systems -- 4.4 Mechanisms Underpinning Other Drug Withdrawal States -- 5 Conclusion -- References. , Pramipexole for the Treatment of Depression: Efficacy and Mechanisms -- 1 Dopaminergic Treatments in Depression -- 2 Pharmacology of Pramipexole -- 3 Pramipexole, an Emerging Treatment for Major Depression? -- 3.1 Efficacy in Randomised Trials -- 3.2 Efficacy in Case Series -- 4 The Neural Architecture of Reward Learning -- 4.1 Neural Circuitry -- 4.2 Computational Accounts of Reward Learning -- 5 Reward Learning in Depression -- 6 Pramipexole and Reward Processing -- 7 Pramipexole Preserves Value Estimates -- 8 Conclusions -- References -- Opioid Mechanisms and the Treatment of Depression -- 1 Introduction -- 2 The Endogenous Opioid System -- 3 The Opioid System and Depression -- 4 Opioidergic Agents in Depression -- 5 Antidepressant Mechanisms of Opioid System Engagement -- 5.1 Monoaminergic Systems -- 5.2 Regulation of the Stress Response and the Hypothalamic-Pituitary-Adrenal (HPA) Axis -- 5.3 Immune System and Inflammation -- 5.4 Brain-Derived Neurotrophic Factor (BDNF) -- 5.5 Intracellular Signalling, Neurogenesis and Neuroplasticity -- 5.6 Opioid System and the Social Brain: Social Pain and Social Reward -- 5.7 Expectancy and Placebo Effects -- 6 Conclusions -- References -- Neuropsychological Effects of Antidepressants: Translational Studies -- 1 Introduction -- 2 The Role of Animal Models in Research into Antidepressant Mechanisms -- 3 Neuropsychological Impairments in Mood Disorders -- 4 Neuropsychological Effects of Antidepressants: Healthy Volunteer and Patient Studies -- 5 Neuropsychological Effects of Antidepressants: Animal Studies -- 6 Animal Models of Reward Learning -- 7 Discussion and Conclusions -- 7.1 Could Different Neuropsychological Effects of Conventional Versus Rapid Acting Antidepressants Explain the Temporal Differ... -- 7.2 Possible Neural Circuits Mediating Affective Biases -- 7.3 Summary and Future Directions. , References -- Ketamine for Major Depressive Disorder -- 1 Introduction -- 2 Beyond the Monoaminergic Hypothesis of Depression -- 3 Clinical Effects of a Single Administration of a Sub-anaesthetic Dose of Ketamine -- 4 How to Extend Ketamine Antidepressant Effect? -- 5 Ketamine and Suicidality -- 6 Ketamine Assisted Psychotherapy -- 7 Ketamine Safety Profile -- 8 Pharmacology of Ketamine -- 8.1 Pharmacokinetics and Route of Administration -- 8.2 Ketamine Molecular Mechanism of Action -- 9 Brain-Imaging Biomarkers of Ketamine Antidepressant Effects -- 9.1 Resting State Functional Magnetic Resonance Imaging (fMRI) Studies -- 9.2 Positron Emission Tomography (PET) Studies -- 9.3 Task-Based fMRI Studies -- 10 Conclusion -- References -- Psilocybin and Other Classic Psychedelics in Depression -- 1 Introduction -- 2 Basic Facts -- 3 Clinical Effects -- 3.1 Psychological Processes -- 4 Brain Mechanisms -- 4.1 Magnetic Resonance Imaging -- 4.2 Electroencephalography -- 4.3 Computational Aspects of Psychedelics in Depression -- 5 Current Research Questions -- 5.1 Duration of Trip for Psychedelics: Why Does This Matter? -- 5.2 Optimal Number of Treatments -- 5.3 Prior Antidepressant Treatment -- 5.4 Psychedelics and Prophylaxis -- 5.5 Can Psychedelics Be Developed that Treat Depression Without Having a Psychedelic Effect? -- 5.6 Legality of Psychedelics -- 6 Final Thoughts -- References -- Microbiota-Gut-Brain Axis and Antidepressant Treatment -- 1 Introduction -- 2 The Gut Microbiota -- 3 Microbiota-Gut-Brain Axis -- 4 Microbiota-Gut-Brain Axis, Brain Function, and Behavior -- 5 Updates to the Pathogenesis and Neurobiology of Depression: A Multifactorial Contribution -- 6 The Microbiome-Gut-Brain Axis and Depression -- 7 Conventional Antidepressant Therapy -- 8 Antidepressants and the Microbiota-Gut-Brain Axis -- 9 Prebiotics and Probiotics. , 10 Future Directions -- References -- Anti-inflammatory Drugs in the Treatment of Depression -- 1 Immune-Mediated Inflammation in the Neurobiology of Depression -- 1.1 General Background -- 1.2 Genetic Data -- 1.3 Epigenetics -- 1.4 Cell Biology in Depression -- 1.4.1 Cell Populations -- 1.4.2 Peripheral -- 1.4.3 Transcriptional Differences -- 1.4.4 Cells Within the CNS -- 1.5 Cellular Mechanisms: The Inflammasome -- 1.6 Adiposity and Aging -- 2 Evidence for the Antidepressant Effects of Anti-inflammatory Medication -- 2.1 Drug Types -- 2.2 Meta-Analytic Data of Drug Effects -- 2.2.1 Meta-Analyses Studies with Depression as a Secondary Measure -- 3 The (Possible) Antidepressant Mechanism of Anti-inflammatory Drugs -- 3.1 Glutamate -- 3.2 Serotonin -- 3.3 IDO and the Kynurenine Pathway -- 3.4 Measuring Mechanism in Clinical Studies -- 4 Future -- 5 Conclusions -- References -- Mechanisms of Action of TMS in the Treatment of Depression -- 1 Introduction -- 2 Neuroanatomical Targets for TMS in Depression -- 2.1 Correlational Mapping of Target Brain Regions for Depression -- 2.2 Causal Mapping of Whole-Brain Networks for Depression -- 3 Functional Connectivity and Therapeutic Effects of TMS in Depression -- 3.1 Characterizing Changes in Functional Connectivity Associated with Response to DLPFC-TMS -- 3.2 Non-DLFPC TMS Targets in Depression: Common or Distinctive Mechanisms? -- 4 Synaptic and Neuroplastic Mechanisms of TMS in Depression -- 4.1 TMS Effects on Plasticity in Local Microcircuits -- 4.2 TMS Effects on Plasticity in Distributed Networks -- 4.3 Modeling TMS in Rodents -- 5 Neuropharmacological Mechanisms of TMS in Depression -- 5.1 Dopaminergic Mechanisms -- 5.2 Glutamatergic Mechanisms -- 6 Unresolved Questions on the Mechanisms of TMS in Depression -- 6.1 Where Are All the TMS `Anti-responders´?. , 6.2 Why Are TMS Clinical Outcomes Not as Heterogeneous as TMS Single-Session Effects? -- 6.3 What Are the Implications of Meta-Plasticity for Therapeutic TMS Protocols? -- 6.4 Synaptic Pro-Kurtosis (SPrK) as a Therapeutic Mechanism for TMS -- 6.5 Implications of the SPrK Model for Interpreting the Neuropathology of Psychiatric Disorders -- 7 Transdiagnostic and Evolutionary Perspectives on the Mechanisms of TMS in Depression -- 8 Summary and Conclusions -- References -- Mechanism of Action of ECT in Depression -- 1 Introduction -- 2 Volumetric Brain Changes -- 3 Structural Connectivity Changes -- 4 Functional Connectivity Changes -- 5 Immune Effects -- 6 Conclusion -- References -- Invasive Neuromodulation Techniques for Treatment-Resistant Depression -- 1 Introduction -- 2 Vagal Nerve Stimulation -- 2.1 Mechanism of Action -- 2.2 Clinical Experience -- 2.3 Conclusions and Future Directions -- 3 Deep Brain Stimulation -- 3.1 Subcallosal Cingulate Gyrus (SCG) -- 3.2 Other DBS Targets -- 3.3 Conclusions -- 4 Epidural Cortical Stimulation -- 5 Conclusions -- References.

Additional Edition: ISBN 3-031-66355-1

Language: English